fFN Rapid Test Strip

Fetal fibronectin, commonly known as fFN, is a protein found at the maternal-fetal interface. It helps maintain the connection between the amniotic sac and the uterine lining. When fetal fibronectin is detected in vaginal secretion during the mid-pregnancy period, it may suggest disruption at the fetal-maternal interface and may help healthcare professionals assess the risk of preterm labor. However, the fFN rapid test strip should not be used alone to diagnose preterm labor. It is a screening-support tool and should be interpreted by trained medical professionals.

The fFN rapid test strip (vaginal secretion) is intended for the qualitative detection of fetal fibronectin in vaginal or cervicovaginal secretion samples. It may help healthcare professionals evaluate possible preterm labor risk, especially when a pregnant patient presents with symptoms such as contractions, pelvic pressure, lower back pain, or changes in vaginal discharge.

Applications

• Pregnancy-care evaluation
• Preterm labor risk assessment support
• Fertility and women’s health diagnostics
• Maternity clinic testing
• Gynecology department testing
• Hospital pregnancy-care support
• Diagnostic laboratory use
• International healthcare distribution

The fFN rapid test strip uses the colloidal gold method, a rapid immunochromatographic testing principle. In this method, colloidal gold-labeled antibodies react with fetal fibronectin in the sample. If fFN is present at a detectable level, the strip produces a visual test line according to the product’s instructions for use.

Benefits

• Easy-to-use strip format
• Rapid visual result interpretation
• No complex instrument required for basic strip reading
• Suitable for professional point-of-care environments
• Helpful for clinics, laboratories, and maternity-care facilities
• Compact format for international distribution

For this product, the correct specimen should be vaginal secretion or cervicovaginal secretion. Urine should not be listed as the specimen unless LARKSOIS Pharma has a validated urine-based fFN product, because standard fFN testing references describe vaginal or cervicovaginal secretion samples.

Guidance

• Collect the sample using the recommended swab or collection system
• Avoid contamination with blood, lubricants, creams, or external materials
• Follow the product IFU for sample preparation and testing time
• Use the strip immediately after opening the sealed pouch
• Read results only within the instructed result window
• Use only by trained healthcare professionals

Note

Proper sample collection is important for reliable results. Collection should follow the official LARKSOIS Pharma product insert.

• The fFN rapid test strip helps support preterm labor risk assessment. Preterm birth can lead to serious newborn health complications, and early risk identification allows healthcare providers to plan monitoring and intervention when needed.
• A negative fFN result is often clinically useful because it may help reassure healthcare professionals that delivery is unlikely in the near term when interpreted correctly with clinical findings.
• A positive result suggests increased risk, but it does not confirm that preterm delivery will happen soon. The result should be reviewed with symptoms, cervical findings, ultrasound assessment, and professional medical judgment.

Steps

• Bring the test strip and collected sample to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect vaginal or cervicovaginal secretion using the recommended swab
• Prepare the sample according to the product IFU
• Apply or dip the sample according to the test instructions
• Place the strip on a clean, flat surface if required
• Read the result within the approved result window

Note

The exact procedure must follow the official LARKSOIS Pharma product insert or IFU supplied with the fFN Rapid Test Strip.

Positive

A positive result means fetal fibronectin has been detected in the vaginal secretion sample. This may indicate increased preterm labor risk, but it does not confirm immediate delivery. Further assessment may include cervical length measurement, symptom review, ultrasound, and clinical monitoring.

Negative

A negative result means fetal fibronectin is not detected or is below the detectable level of the test. This may suggest a lower short-term risk of preterm birth when interpreted correctly with clinical findings.

Invalid

If the control line does not appear, the result is invalid. The test should be repeated with a new strip and fresh sample according to the IFU.

Certain conditions may affect the accuracy of an fFN rapid test strip result. Proper sample collection helps reduce inaccurate results.

Instructions

• Recent sexual intercourse may affect results
• Recent vaginal examination may affect results
• Bleeding may affect the sample
• Vaginal infection may influence test accuracy
• Lubricants, creams, or vaginal medicines may interfere
• Cervical inflammation may affect interpretation
• Recent cervical procedures may influence results

Note

For best performance, sample collection should be done before digital cervical examination, before use of lubricants, and according to the test instructions.

Instructions

• Store in a dry place
• Keep away from direct sunlight
• Do not freeze unless stated on the label
• Keep the strip sealed until use
• Do not use damaged or expired strips
• Follow temperature conditions printed on the package

Note

Proper storage is important for maintaining product performance across international shipping, warehousing, and clinical-use environments.

Instructions

• For professional diagnostic screening support only
• Use vaginal secretion or cervicovaginal secretion samples only
• Do not use urine unless specifically validated by the product IFU
• Do not reuse the strip
• Do not use expired or damaged strips
• Do not use as the only basis for diagnosing preterm labor
• Results should be interpreted by trained healthcare professionals with clinical findings
• Follow local pregnancy-care and obstetric diagnostic guidelines

LARKSOIS Pharma offers professional diagnostic solutions with a focus on quality, reliability, and international market suitability. The fFN rapid test strip by LARKSOIS Pharma is designed for women’s health professionals who require a practical, rapid, and easy-to-use testing format.

Advantages

• International-quality diagnostic product positioning
• Professional fertility and pregnancy-care application
• Colloidal gold rapid test technology
• Vaginal secretion sample compatibility
• Convenient strip-based format
• Suitable for hospitals, clinics, and diagnostic laboratories
• Useful for global distributors and healthcare procurement